Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the combination treatment of CTS-1027, pegylated
interferon and ribavirin can improve the response rates in HCV patients who did not
previously respond to pegylated interferon and ribavirin therapy.